Vasoconstrictor and Systemic Activities of Topical Steroids

Child, Korean J

doi:10.1001/archderm.1968.01610100047006

Cited by 33 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, the young girl who presented with amenorrhoea may have had her menarche 10 days after starting CB due to a prostagenic effect rather than improvement of her coeliac disease, since topically active steroids are several times more active in this respect than progesterone [23].…”

Section: Discussionmentioning

confidence: 99%

Clinical, Biochemical and Morphological Responses of Patients with Villous Atrophy to Oral Betamethasone Valerate and Clobetasone Butyrate

Bramble¹,

Watson²,

Scott³

et al. 1981

Digestion

View full text Add to dashboard Cite

10 patients with sub-total villous atrophy were given the topical corticosteroids betamethasone valerate or clobetasone butyrate for a period of 4 months whilst continuing on a normal diet. 5 patients improved symptomatically while red cell folate, urinary xylose and faecal fat excretion also improved. Brush border enzymes increased in patients treated with higher dosages of each drug. Enterocyte height increased and intra-epithelial lymphocytes were significantly decreased although overall morphological appearances remained indistinguishable from untreated coeliac disease. Suppression of the pituitary adrenal axis occurred in 8 patients and there did not appear to be useful separation of topical from systemic activity. These compounds offer no advantage over prednisolone in non-responsive coeliac disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical, Biochemical and Morphological Responses of Patients with Villous Atrophy to Oral Betamethasone Valerate and Clobetasone Butyrate

Bramble¹,

Watson²,

Scott³

et al. 1981

Digestion

View full text Add to dashboard Cite

show abstract

“…Thus, absorption of topically applied compounds in rodent skin can exceed human skin by 10 times. Anti‐inflammatory activities of GCs also differ in rats and humans (89), and, since anti‐inflammatory potencies and atrophogenic potential usually closely correlates in the classical GCs, the relative dermal atrophy potencies are also expected to vary between species (63).…”

Section: Determining Atrophogenic Potentialmentioning

confidence: 99%

Glucocorticoid therapy‐induced skin atrophy

Schoepe¹,

Schäcke²,

May³

et al. 2006

Experimental Dermatology

289

282

View full text Add to dashboard Cite

Glucocorticoids (GCs) are highly effective for the topical treatment of inflammatory skin diseases. Their long-term use, however, is often accompanied by severe and partially irreversible adverse effects, with atrophy being the most prominent limitation. Progress in the understanding of GC-mediated molecular action as well as some advances in technologies to determine the atrophogenic potential of compounds has been made recently. It is likely that the detailed mechanisms of GC-induced skin atrophy will be discovered and in vitro models for the reliable prediction of atrophy will be established in the foreseeable future. This knowledge will not only facilitate safety profiling of established drugs but will also foster further drug discovery by improving compound characterization processes. New insights into GC modes of action will guide optimization strategies aiming at novel GC receptor ligands with improved effect/side effect profile.

show abstract

“…An evident con of many in vivo models is, however, their still limited predictivity for the human situation. Anti-inflammatory activities of GCs differ in rats and humans, 44 and, since anti-inflammatory potencies and atrophogenic potential usually closely correlate in the classical GCs, the relative dermal atrophogenic potencies are also expected to vary between the species. 39 Compared to humans, the hairless rat seems to be more sensitive to atrophy following topical GC treatment.…”

Section: 34mentioning

confidence: 99%